| Literature DB >> 26029481 |
Dotun Ogunyemi1, Jun Xu2, Arnold M Mahesan3, Steve Rad3, Eric Kim2, Jacqueline Yano3, Carolyn Alexander3, Jerome I Rotter4, Y-D Ida Chen5.
Abstract
OBJECTIVE: To profile the differential gene expression of the KEGG Adipocytokine Signaling pathway in omental compared to subcutaneous tissue in normal pregnancy. STUDYEntities:
Keywords: Adipocytokine Pathway; Adipose Tissue; Insulin Resistance; Pregnancy
Year: 2013 PMID: 26029481 PMCID: PMC4447103 DOI: 10.4236/jdm.2013.32013
Source DB: PubMed Journal: J Diabetes Mellitus ISSN: 2160-5831
Figure 1KEGG Adipocytokine Signaling Pathway.
Downregulated genes are those marked with red stars: ADIPO (Adiponectin), SHP2 (Protein Tyrosine Phosphatase, Non-Receptor Type 11—PTPN11), RXR (Retinoid X-Receptor, alpha), IRS1 (Insulin Receptor Substrate 1), FATCD36 (CD36 molecule, thrombospondin receptor), FACS (acyl-CoA synthetase long-chain family member 1—ACSL1); Upregulated genes are marked with blue stars as they appear in the KEGG gene listing: SLC20A1 (shown as GLUT-1) and CPT1C (listed under CPT-1). Legend of KEGG gene symbols and full gene names for differentially expressed genes appears below [6,7].
Legend of differentially expressed genes in KEGG adipocytokine signaling pathway (Figure 1).
Note where gene symbols/names are separated by a comma, this denotes different genes, but where they are separated by the word “or” this denotes they are synonyms.
Downregulated/upregulated genes in each gene list are underlined.
Figure 2Heat map of differentially expressed genes (DEGs) in Adipocytokine Signaling Pathway. Each column on the horizontal axis represents a tissue sample. (14 subjects) × (2 tissue samples each, omental and subcutaneous) = 28 total tissue samples. Each row on the vertical axis represents one of the 8 DEGs.
Primer sequences for PCR validation of microarray results.
| GeneSymbol: | REFSEQ_ID: | 5’ to 3’ | Reverse primer: |
|---|---|---|---|
| Forward primer: | |||
| GAPDH | NM_002046 | c a g g t g g t c t c c t c t g a c t t | c c a a a t t c g t t g t c a t a c c a |
| IL-6 | NM_000600.3 | g a a a g t g g c t a t g c a g t t t g a | g g t a a g c c t a c a c t t t c c a a g a |
| IL-1B | NM_000576 | g g g c a a g a a g t a g c a g t g t c | g a g a g c a c a c c a g t c c a a a |
| CLDN1 | NM_021101 | c c t g g a t t t g a g t c t t g g t g | c c g c t t a c a g a t g a a g c a a t |
| ADIPOQ | NM_004797 | t g g c t a t g c t c a c a g t c t c a | t c t c t c t g t g c c t c t g g t t c |
| CFB | NM_001710 | c a g a c t a t c a g g c c c a t t t g | g t t g c t g g c a a g t g g t a g t t |
| IRS1 | NM_005544 | a c a c c g a g g a t a a a c a c t g g | c t a c g g a a g g a c c a c a a a g a |
Patient characteristics for study group.
| Race | Age | Gestational | Birth | Maternal | BMI | |
|---|---|---|---|---|---|---|
| Patient 1 | Afr Am | 33 | 40 + 0 | 3213 | 75.8 | 22.2 |
| Patient 2 | Afr Am | 28 | 39 + 0 | 3950 | 77.1 | 25.5 |
| Patient 3 | Afr Am | 41 | 39 + 1 | 3210 | 88.9 | 26.3 |
| Patient 4 | Asian | 30 | 39 + 5 | 2760 | 59 | 20.7 |
| Patient 5 | Asian | 31 | 38 + 2 | 3230 | 78.9 | 23 |
| Patient 6 | Caucasian | 20 | 39 + 0 | 3400 | 75.4 | 20.8 |
| Patient 7 | Caucasian | 38 | 39 + 0 | 3493 | 89 | 22.3 |
| Patient 8 | Caucasian | 36 | 37 + 2 | 2850 | 78.4 | 24.9 |
| Patient 9 | Hispanic | 37 | 39 + 0 | 2769 | 56.7 | 18.7 |
| Patient 10 | Hispanic | 37 | 39 + 0 | 3420 | 58 | 21 |
| Patient 11 | Hispanic | 26 | 39 + 1 | 3460 | 82.6 | 21.7 |
| Patient 12 | Hispanic | 38 | 38 + 5 | 2630 | 77.1 | 23 |
| Patient 13 | Hispanic | 32 | 39 + 0 | 3760 | 84.8 | 25.8 |
| Patient 14 | Hispanic | 23 | 38 + 5 | 3210 | 95.3 | 29.7 |
| Mean | 32.1 | 39 + 0 | 3240 | 77 | 23.3 | |
| Standard deviation | 6.21 | 4.37 days | 384.7 | 12.3 | 2.88 | |
Afr Am = African American; Age in years; Gestational Age in weeks + days; Birth weight in grams; Maternal weight at delivery in kilograms.
Figure 3ANOVA model used to evaluate the impacts of the potential confounding variables: fat, race, BMI, fat and race in the differentially expressed genes in the study population. The horizontal column indicates the Mean F Ratio while the various factors analyzed in the multi factor ANOVA are listed horizontally along the x-axis. Any factor that has a Mean F Ratio more than error (1.00) is considered “significant”.
Differentially expressed genes in omental relative to subcutaneous adipose tissue.
| Gene symbol | Gene name | Fold-change | P-value | Function |
|---|---|---|---|---|
| IRS1 (IRS) | Insulin Receptor Substrate-1 | −1.771 63 | 0.000 014 6 | Interacts with insulin receptor and enables insulin metabolic actions by signaling PI3K pathway |
| ADIPOQ (ADIPO) | Adiponectin, C1Q and collagen domain containing | −1.667 34 | 0.039 814 | Signals increased glucose uptake via the GLUT transporters, modulates fatty acid catabolism |
| RXRA (RXR) | Retinoid × Receptor, alpha | −1.614 26 | 0.000 015 | Activation of PPAR-alpha to promote uptake and utilization of fatty acids |
| CD36 | Thrombospondin receptor | −2.058 39 | 0.000 181 | Uptake of free fatty acids (FFA) from plasma |
| ACSL1 (FACS) | Acyl-CoA synthetase long-chain family member 1 | −1.701 68 | 0.003 205 | FFA activation for triacylglycerol synthesis |
| PTPN11 (SHP2) | Protein tyrosine phosphatase, non-receptor type 11 | −1.733 8 | 0.0 000 256 | Has regulatory role in mitogenic activation, metabolic control, transcription regulation, and cell migration |
| SLC20A1 (GLUT1) | Solute carrier family 2(facilitated glucose transporter), member 1 | 1.589 51 | 0.000 079 4 | Plasma membrane glucose transporter, responsible for basal glucose intake In adipose and skeletal muscle |
| CPT1C (CPT-1) | Carnitine palmitoyltransfer-ase 1C | 1.703 3 | 0.000 060 2 | Function not well understood, believed to play a role in regulation of energy homeostasis |
Real-time PCR validation of microarray results.
| Fold Change | |||
|---|---|---|---|
| Gene | Ref_seq | Microarray | RT-PCR |
| IL-6 | NM_000600 | 2.19 | 1.23 |
| IL-1B | NM_000576 | 2 | 1.31 |
| CLDN1 | NM_021101 | 18.61 | 13.89 |
| ADIPOQ | NM_004797 | −1.67 | −1.58 |
| CFB | NM_001710 | 10.62 | 11.6 |
| IRS1 | NM_005544 | −1.77 | −1.48 |
| PLA2G2A | NM_000300 | 4.48 | 3.5 |
| KEGG Gene Symbol | Official Gene Symbol(s) | Gene name(s) |
|---|---|---|
| Downregulated genes | ||
| FATCD36 | CD36 | CD36 molecule (thrombospondin receptor) |
| FACS | ACSL1, ACSL3, ACSL4, ACSL5, ACSL6 | acyl-CoA synthetase long-chain family member 1, 3, 4, 5, and 6 |
| IRS | IRS1, IRS2, IRS4 | insulin receptor substrate 1, 2, and 4 |
| SHP2 | LOC344593 or LOC442113 or PTPN11 | protein tyrosine phosphatase, non-receptor type 11 |
| ADIPO | ADIPOQ | adiponectin, C1Q and collagen domain containing |
| RXR | RXRA, RXRB, RXRG | retinoid × receptor alpha, beta, and gamma |
| Upregulated genes | ||
| GLUT1/4 | SLC2A1, SLC2A4 | solute carrier family 2 (facilitated glucose transporter), member 1, solute carrier family 2 (facilitated glucose transporter), member 4 |
| CPT-1 | CPT1A, CPT1C, CPT1B or CHKB | carnitine palmitoyltransferase 1A (liver), carnitine palmitoyltransferase 1C, carnitine palmitoyltransferase 1B (muscle) or choline kinase beta |
Note where gene symbols/names are separated by a comma, this denotes different genes, but where they are separated by the word “or” this denotes they are synonyms.
Downregulated/upregulated genes in each gene list are underlined.